These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 23258572)

  • 21. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
    J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
    Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
    Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
    Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
    Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
    Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
    Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    Clin Res Cardiol; 2021 Aug; 110(8):1234-1248. PubMed ID: 33301080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
    Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations Between Depressive Symptoms and HFpEF-Related Outcomes.
    Chandra A; Alcala MAD; Claggett B; Desai AS; Fang JC; Heitner JF; Liu J; Pitt B; Solomon SD; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2020 Dec; 8(12):1009-1020. PubMed ID: 32919912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
    Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
    Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
    JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.